Iranian Journal of Medical Sciences

CRISPR/Cas9-Targeted Deletion of Methyltransferase-like 3 (METTL3) in HepG2 Cells: A Preliminary In Vitro Platform Toward Advanced m⁶A‑Associated MASLD Models

Document Type : Original Article(s)

Authors

1 Department of Molecular Medicine, School of Advanced Medical Technologies, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Shiraz Institute for Stem Cell and Regenerative Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

3 Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

5 Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

6 Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran

7 Department of Medical Biotechnology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

8 Biotechnology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

9 Genetics and Environmental Hazards Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

10 Mother and Newborn Health Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

11 Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

10.30476/ijms.2026.110780.4665
Abstract
Background: Metabolic dysfunction‑associated steatotic liver disease (MASLD) has emerged as a major contributor to chronic liver pathology. N⁶‑methyladenosine (m⁶A) RNA methylation, catalyzed by methyltransferase‑like 3 (METTL3), has been implicated in MASLD in a context‑ and stage‑dependent manner, underscoring the need for genetically defined experimental models. This study aimed to establish a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9)‑based genome‑editing strategy for targeted deletion of METTL3 in HepG2 cells as a preliminary in vitro system to support future investigations of m⁶A‑dependent regulatory mechanisms in MASLD.
Methods: A CRISPR/Cas9 approach using two single-guide RNAs (sgRNAs) targeting introns 2 and 10 of METTL3 was employed to induce large-scale genomic excision. The sgRNAs, cloned into the PX458 vector, were co‑transfected into HepG2 cells, followed by fluorescence‑activated cell sorting (FACS) enrichment of green fluorescent protein (GFP)‑positive cells. Targeted deletion was assessed by gap-polymerase chain reaction (gap-PCR) and Sanger sequencing, and editing efficiency was estimated using tracking of indels by decomposition (TIDE) and CRISPR indel detector (CRISPR-ID) analyses.
Results: Gap‑PCR produced an approximately 500 bp amplicon consistent with the predicted METTL3 deletion. Sanger sequencing confirmed precise excision with a frameshift predicted to disrupt the METTL3 open reading frame. The TIDE analysis indicated an overall editing efficiency of approximately 34%.
Conclusion: This study demonstrated a CRISPR/Cas9‑based strategy for targeted deletion of METTL3 in HepG2 cells, establishing an initial genetically defined in vitro framework that provided a foundation for the future development of m⁶A‑associated MASLD model systems.

Highlights

Faezeh Shafiei (Google Scholar) 
Ali Dadbinpour (Google Scholar)

Keywords


1.     Xu B, Li H, Pi Y, Li K. Global, regional and national burden of Metabolic dysfunction-associated steatotic liver disease in adolescents and adults aged 15-49 years from 1990 to 2021: results from the 2021 Global Burden of Disease study. Front Med (Lausanne). 2025;12:1568211. doi: 10.3389/fmed.2025.1568211. PubMed PMID: 40636383; PubMed Central PMCID: PMC12237898.
2.     Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:S32-S50. doi: 10.3350/cmh.2024.0431. PubMed PMID: 39159948; PubMed Central PMCID: PMC11925440.
3.     Mejia-Guzman JE, Belmont-Hernandez RA, Chavez-Tapia NC, Uribe M, Nuno-Lambarri N. Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies. Int J Mol Sci. 2025;26. doi: 10.3390/ijms26072959. PubMed PMID: 40243565; PubMed Central PMCID: PMC11988898.
4.     Dua A, Kumari R, Singh M, Kumar R, Pradeep S, Ojesina AI, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes. Front Med (Lausanne). 2025;12:1618275. doi: 10.3389/fmed.2025.1618275. PubMed PMID: 40893881; PubMed Central PMCID: PMC12392282.
5.     Li Y, Yang P, Ye J, Xu Q, Wu J, Wang Y. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23:117. doi: 10.1186/s12944-024-02108-x. PubMed PMID: 38649999; PubMed Central PMCID: PMC11034170.
6.     Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20:608-24. doi: 10.1038/s41580-019-0168-5. PubMed PMID: 31520073.
7.     Yang Y, Cai J, Yang X, Wang K, Sun K, Yang Z, et al. Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. Mol Ther. 2022;30:2342-53. doi: 10.1016/j.ymthe.2022.02.021. PubMed PMID: 35192934; PubMed Central PMCID: PMC9171149.
8.     Zha X, Gao Z, Li M, Xia X, Mao Z, Wang S. Insight into the regulatory mechanism of m(6)A modification: From MAFLD to hepatocellular carcinoma. Biomed Pharmacother. 2024;177:116966. doi: 10.1016/j.biopha.2024.116966. PubMed PMID: 38906018.
9.     Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93-5. doi: 10.1038/nchembio.1432. PubMed PMID: 24316715; PubMed Central PMCID: PMC3911877.
10.  Cheng W, Li M, Zhang L, Zhou C, Yu S, Peng X, et al. New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC. Front Pharmacol. 2022;13:973116. doi: 10.3389/fphar.2022.973116. PubMed PMID: 36120320; PubMed Central PMCID: PMC9471244.
11.  Li Q, Xiang J. METTL3 promotes the progression of non-alcoholic fatty liver disease by mediating m6A methylation of FAS. Sci Rep. 2025;15:6162. doi: 10.1038/s41598-025-90419-z. PubMed PMID: 39979577; PubMed Central PMCID: PMC11842791.
12.  Li Y, Zhang Q, Cui G, Zhao F, Tian X, Sun BF, et al. m(6)A Regulates Liver Metabolic Disorders and Hepatogenous Diabetes. Genomics Proteomics Bioinformatics. 2020;18:371-83. doi: 10.1016/j.gpb.2020.06.003. PubMed PMID: 33160098; PubMed Central PMCID: PMC8242261.
13.  Xie W, Ma LL, Xu YQ, Wang BH, Li SM. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism. Biochem Biophys Res Commun. 2019;518:120-6. doi: 10.1016/j.bbrc.2019.08.018. PubMed PMID: 31405565.
14.  Li Y, Zhang D, Gao Y, Wang P, Wang Z, Zhang B, et al. METTL3 exacerbates insulin resistance in hepatocytes by regulating m(6)A modification of cytochrome P450 2B6. Nutr Metab (Lond). 2023;20:40. doi: 10.1186/s12986-023-00762-z. PubMed PMID: 37710320; PubMed Central PMCID: PMC10502999.
15.  Peng Z, Gong Y, Wang X, He W, Wu L, Zhang L, et al. METTL3-m(6)A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease. Mol Ther. 2022;30:932-46. doi: 10.1016/j.ymthe.2021.09.016. PubMed PMID: 34547464; PubMed Central PMCID: PMC8821937.
16.  Li X, Yuan B, Lu M, Wang Y, Ding N, Liu C, et al. The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. Nat Commun. 2021;12:7213. doi: 10.1038/s41467-021-27539-3. PubMed PMID: 34893641; PubMed Central PMCID: PMC8664922.
17.  Dai G, Huang S, Li Y, Tu X, Xia J, Zhou Z, et al. Mettl3-mediated m(6)A modification plays a role in lipid metabolism disorders and progressive liver damage in mice by regulating lipid metabolism-related gene expression. Aging (Albany NY). 2023;15:5550-68. doi: 10.18632/aging.204810. PubMed PMID: 37335109; PubMed Central PMCID: PMC10333091.
18.  Liao X, Liu L, Du J, Fan H, Yu Y, Luo Y, et al. METTL3 inhibits liver fibrosis via RBX1 stability and TXNIP-mediated ferroptosis. Hepatol Commun. 2025;9. doi: 10.1097/HC9.0000000000000752. PubMed PMID: 40658786; PubMed Central PMCID: PMC12263036.
19.  Pan XY, Bi YH, Cheng M, Qian ZZ, Wang L, You HM, et al. METTL3 facilitates hepatic fibrosis progression via m6A-YTHDF2-dependent silencing of GPR161. bioRxiv. 2021:2021.12.15.472749. doi: 10.1101/2021.12.15.472749.
20.  Qin Y, Li B, Arumugam S, Lu Q, Mankash SM, Li J, et al. m(6)A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. Cell Rep. 2021;37:109968. doi: 10.1016/j.celrep.2021.109968. PubMed PMID: 34758326; PubMed Central PMCID: PMC8667589.
21.  Cui B, Tu S, Li H, Zeng Z, Xiao R, Guo J, et al. METTL3 knockout accelerates hepatocarcinogenesis via inhibiting endoplasmic reticulum stress response. FEBS Open Bio. 2025;15:1144-58. doi: 10.1002/2211-5463.70023. PubMed PMID: 40103332; PubMed Central PMCID: PMC12226423.
22.  Pan Y, Chen H, Zhang X, Liu W, Ding Y, Huang D, et al. METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. Cell Rep Med. 2023;4:101144. doi: 10.1016/j.xcrm.2023.101144. PubMed PMID: 37586322; PubMed Central PMCID: PMC10439254.
23.  Poh HX, Mirza AH, Pickering BF, Jaffrey SR. Alternative splicing of METTL3 explains apparently METTL3-independent m6A modifications in mRNA. PLoS Biol. 2022;20:e3001683. doi: 10.1371/journal.pbio.3001683. PubMed PMID: 35853000; PubMed Central PMCID: PMC9295969.
24.  Smith I, Greenside PG, Natoli T, Lahr DL, Wadden D, Tirosh I, et al. Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map. PLoS Biol. 2017;15:e2003213. doi: 10.1371/journal.pbio.2003213. PubMed PMID: 29190685; PubMed Central PMCID: PMC5726721.
25.  Goel K, Ploski JE. RISC-y Business: Limitations of Short Hairpin RNA-Mediated Gene Silencing in the Brain and a Discussion of CRISPR/Cas-Based Alternatives. Front Mol Neurosci. 2022;15:914430. doi: 10.3389/fnmol.2022.914430. PubMed PMID: 35959108; PubMed Central PMCID: PMC9362770.
26.  Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5:1. doi: 10.1038/s41392-019-0089-y. PubMed PMID: 32296011; PubMed Central PMCID: PMC6946647.
27.  Tuladhar R, Yeu Y, Tyler Piazza J, Tan Z, Rene Clemenceau J, Wu X, et al. CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulation. Nat Commun. 2019;10:4056. doi: 10.1038/s41467-019-12028-5. PubMed PMID: 31492834; PubMed Central PMCID: PMC6731291.
28.  Smits AH, Ziebell F, Joberty G, Zinn N, Mueller WF, Clauder-Munster S, et al. Biological plasticity rescues target activity in CRISPR knock outs. Nat Methods. 2019;16:1087-93. doi: 10.1038/s41592-019-0614-5. PubMed PMID: 31659326.
29.  Fazelzadeh Haghighi M, Jafari Khamirani H, Fallahi J, Monfared AA, Ashrafi Dehkordi K, Tabei SMB. Novel insight into FCSK-congenital disorder of glycosylation through a CRISPR-generated cell model. Mol Genet Genomic Med. 2024;12:e2445. doi: 10.1002/mgg3.2445. PubMed PMID: 38722107; PubMed Central PMCID: PMC11080630.
30.  Concordet JP, Haeussler M. CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res. 2018;46:W242-W5. doi: 10.1093/nar/gky354. PubMed PMID: 29762716; PubMed Central PMCID: PMC6030908.
31.  Bae S, Park J, Kim JS. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics. 2014;30:1473-5. doi: 10.1093/bioinformatics/btu048. PubMed PMID: 24463181; PubMed Central PMCID: PMC4016707.
32.  Montague TG, Cruz JM, Gagnon JA, Church GM, Valen E. CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res. 2014;42:W401-7. doi: 10.1093/nar/gku410. PubMed PMID: 24861617; PubMed Central PMCID: PMC4086086.
33.  Dara M, Razban V, Talebzadeh M, Moradi S, Dianatpour M. Using CRISPR/Cas9 System to Knock out Exon 48 in DMD Gene. Avicenna J Med Biotechnol. 2021;13:54-7. doi: 10.18502/ajmb.v13i2.5517. PubMed PMID: 34012519; PubMed Central PMCID: PMC8112140.
34.  Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42:e168. doi: 10.1093/nar/gku936. PubMed PMID: 25300484; PubMed Central PMCID: PMC4267669.
35.  Dehairs J, Talebi A, Cherifi Y, Swinnen JV. CRISP-ID: decoding CRISPR mediated indels by Sanger sequencing. Sci Rep. 2016;6:28973. doi: 10.1038/srep28973. PubMed PMID: 27363488; PubMed Central PMCID: PMC4929496.
36.  Wang X, Zhang L, Dong B. Molecular mechanisms in MASLD/MASH-related HCC. Hepatology. 2025;82:1303-24. doi: 10.1097/HEP.0000000000000786. PubMed PMID: 38349726; PubMed Central PMCID: PMC11323288.
37.  Piao X, Meng D, Zhang X, Song Q, Lv H, Jia Y. Dual-gRNA approach with limited off-target effect corrects C9ORF72 repeat expansion in vivo. Sci Rep. 2022;12:5672. doi: 10.1038/s41598-022-07746-8. PubMed PMID: 35383205; PubMed Central PMCID: PMC8983752.
38.  Haaker MW, Chang JC, Chung BK, Pieper TS, Noe F, Wang T, et al. Cellular Crosstalk Promotes Hepatic Progenitor Cell Proliferation and Stellate Cell Activation in 3D Co-culture. Cell Mol Gastroenterol Hepatol. 2025;19:101472. doi: 10.1016/j.jcmgh.2025.101472. PubMed PMID: 39892785; PubMed Central PMCID: PMC11968293.
39.  Messner S, Fredriksson L, Lauschke VM, Roessger K, Escher C, Bober M, et al. Transcriptomic, Proteomic, and Functional Long-Term Characterization of Multicellular Three-Dimensional Human Liver Microtissues. Appl In Vitro Toxicol. 2018;4:1-12. doi: 10.1089/aivt.2017.0022. PubMed PMID: 32953943; PubMed Central PMCID: PMC7500040.
40.  Sani F, Soufi Zomorrod M, Azarpira N, Soleimani M. The Effect of Mesenchymal Stem Cell-Derived Exosomes and miR17-5p Inhibitor on Multicellular Liver Fibrosis Microtissues. Stem Cells Int. 2023;2023:8836452. doi: 10.1155/2023/8836452. PubMed PMID: 37576406; PubMed Central PMCID: PMC10421706.
41.   Ardisasmita AI, Schene IF, Joore IP, Kok G, Hendriks D, Artegiani B, et al. A comprehensive transcriptomic comparison of hepatocyte model systems improves selection of models for experimental use. Commun Biol. 2022;5:1094. doi: 10.1038/s42003-022-04046-9. PubMed PMID: 36241695; PubMed Central PMCID: PMC9568534.

Articles InPress, Corrected Proof
Available Online from 18 November 2026


  • Received 21 February 2026
  • Revised 17 May 2026
  • Accepted 03 July 2026